

The measurement of health-related quality of life was done using the Brazilian version of 12-Item Short-Form Health Survey Version 2 (SF-12v2) [25]. The SF-12v2 encompasses eight subscales grouped into two larger dimensions: the Physical Component Summary (PCS) and Mental Component Summary (MCS). For both PCS and MCS, the score ranges from 0 to 100 points, where higher scores mean better quality of life.

The study protocol was approved by the institutional ethics committee, and all enrolled patients gave written informed consent.

2.2. DEFINITIONS OF NEUROLOGICAL AND PSYCHIATRIC PARAMETERS

The definition of chorea and tics followed standard clinical criteria [5, 26]. Basal ganglia motor dysfunction (BGMD) was clinically defined by the presence hyperkinetic movement disorders associated with RF, suggesting the involvement of frontostriatal motor circuit, in other words patients with well-documented history of SC during childhood or adolescence, and patients with current chorea and/or tics on examination [5, 27].

Seizures were defined according to the International League Against Epilepsy (ILAE) 2017 seizure classification subtypes [28]. The diagnosis of migraines was done according to the criteria of the International Classification of Headache Disorders, 3rd edition (ICHD-3) [29]. Cognitive complaints consisted of subjective complaints about difficulties in attention, memory and execution/planning of daily tasks reported by the patients [30].

The diagnosis of major depressive disorder and generalized anxiety disorder was assigned for patients currently meeting the DSM-5 criteria [26]. Obsessive-compulsive symptoms (OCS) referred to recurrent or persistent thoughts experienced as intrusive and/or repetitive behaviors or mental acts done in response to obsessions. The Hospital Anxiety and Depression Scale (HADS) was used to quantify anxiety and depressive symptoms, and the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) was applied to measure the severity of OCS [22, 23].

The overall cognitive function was assessed using the Brazilian version of the Mini-Mental State Examination (MMSE), while frontal-executive functions were assessed using the Brazilian version of the Frontal Assessment Battery (FAB) [20, 21]. We defined patients with low MMSE score as those performing lower than the proposed MMSE cutting-off scores adjusted for years of schooling [20].

2.3. STATISTICAL ANALYSIS

Continuous data were expressed as mean \pm s.d. or as median and interquartile range, depending on normality distribution. Categorical data were summarized as numbers and percentages. The variables of RHD patients with or without BGMD were compared using Fisher exact test, unpaired Student's t test or Mann-Whitney U test, as appropriate. Logistic regression analysis was performed to determine which variables were independently associated with BGMD. Demographic, neurological and psychiatric variables that were found to be significantly associated with BGMD in univariate analysis were included in the multivariable logistic regression analysis. The potential predictive variables of BGMD included in multivariate analysis were age, migraine, generalized anxiety disorder, major depressive disorder and Y-BOCS. A value of $p < 0.05$ was considered significant.

3. RESULTS

3.1. CLINICAL FEATURES

Demographic and clinical characteristics are summarized in Table 1. Among 56 patients with RHD initially invited to participate, 50 patients were enrolled in the study (Figure 1). Forty-two subjects (84%) were female, and the majority of patients were diagnosed with chronic RHD approximately nine years before the current assessment.

At the time of assessment, severe functional limitation (NYHA functional class III-IV) was found in 24% of patients (Table 1). Mitral valve was affected in 47 patients (94%), with 46 patients (92%) previously been submitted to mitral valve intervention, mainly percutaneous mitral balloon commissurotomy (84%). Twenty-five patients (50%) presented with isolated

VARIABLES*	VALUE
Age (years)	43.2 ± 10.8
Female gender	42 (84)
Schooling (years)	8.5 ± 4.3
Time since diagnosis of rheumatic fever (years)	9.0 [5/22]
NYHA functional class	I/II 38 (76)
	III/IV 12 (24)
Systolic blood pressure (mmHg)	111 ± 14
Diastolic blood pressure (mmHg)	73 ± 10
12-Item Short-Form Health Survey†	
Physical Component Summary	45.5 ± 9.9
Mental Component Summary	44.4 ± 13.1
Neurological and psychiatric characteristics	
Current or history of chorea‡	24 (48)
Tics	9 (18)
Basal ganglia motor dysfunction§	18 (36)
Obsessive-compulsive symptoms	24 (48)
Major depressive disorder	17 (34)
Generalized anxiety disorder	27 (54)
Seizures	9 (18)
Migraine	26 (52)
Cognitive complaints¶	33 (66)

Table 1 Clinical, neurological and psychiatric features of the study population.

* Data are expressed as the mean value ± SD, median (interquartile range), or absolute numbers (percentage).

† Revised form of the 12-Item Short-Form Health Survey.

‡ Patients with chorea observed in current neurologic examination plus patients with well-documented history of Sydenham's chorea.

§ Basal ganglia motor dysfunction includes patients with well-documented diagnosis of Sydenham's chorea and patients with current chorea and/or tics.

¶ Patients with subjective complaints about difficulties in attention, memory and execution/planning of daily tasks.




Figure 1 Flow chart of study population.

mitral valve lesion, 21 (42%) had both mitral and aortic valves lesions, and one (2%) had the involvement of three valves, including tricuspid valve. Most patients (74%) had mixed mitral valve disease with predominance of mitral stenosis. Only three patients had aortic valve disease, predominantly aortic insufficiency.

Patients had low scores in both physical (45.5 ± 9.9) and mental components (44.4 ± 13.1) of SF-12v2, suggesting impairment of quality of life, but they were not associated with the severity of cardiac symptoms.

3.2. NEUROLOGICAL AND PSYCHIATRIC MANIFESTATIONS

Neurological and psychiatric symptoms were found in 41 (82%) patients. Nine patients (18%) did not present any neurological or psychiatric symptoms. Chorea was observed in 11 (22%) patients at examination and two other patients had a prior diagnosis of SC. Chronic tic disorders were present in 9 (18%) patients, and 4 (8%) of these patients also exhibited chorea. Therefore, clinically-determined BGMD was detected in 18 patients (36%) (Table 1). Seizures and subjective cognitive complaints were evident in 9 (18%) and 33 (66%) patients, respectively. Migraine was present in 26 (52%) patients. All patients who reported seizures had unrevealing brain CT or MRI scans.

OCS were observed in 24 (48%) patients, while major depressive disorder and generalized anxiety disorder was observed, respectively, in 17 (34%) and 27 (54%) patients. The main OCS were symmetry/ordering (22%), and contamination/cleaning (10%). Other OCS as damage or harmful thoughts (4%) and hoarding (2%) were less frequent. Five (10%) patients had two or more different OCS concomitantly. Psychosis was not found in the study population.

3.3. VARIABLES ASSOCIATED WITH BASAL GANGLIA MOTOR DYSFUNCTION

Demographic and clinical features according to BGMD are summarized in Table 2. Patients with BGMD were younger than patients without BGMD ($p = 0.032$), without differences regarding sex and years of schooling. No cardiologic or echocardiographic parameters were associated with BGMD (Table 2).

CLINICAL PARAMETERS*	PATIENTS WITHOUT BASAL GANGLIA MOTOR DYSFUNCTION (N = 32)	PATIENTS WITH BASAL GANGLIA MOTOR DYSFUNCTION (N = 18)	P VALUE
Age (years)	45.7 ± 10.9	38.9 ± 9.4	0.032
Female gender (n/%)	26 (81)	16 (89)	0.694
Schooling (years)	8.5 ± 4.8	8.2 ± 3.5	0.685
NYHA class III-IV (n/%)	9 (28)	3 (17)	0.497
Valvar intervention (n/%)	30 (94)	16 (89)	0.612
Mitral valve area (cm ²)	1.00 [0.83/1.40]	0.90 [0.77/1.14]	0.280
Left ventricular ejection fraction (%)	65 [57/69]	66 [62/69]	0.424
Left atrial volume (mL/m ²)	55.5 [45/66]	51.3 [47.6/59.2]	0.534
Atrial fibrillation (n/%)	8 (25)	2 (11)	0.452
Mitral mean gradient (mmHg)	8.5 [6.5/14]	9.5 [8/13.7]	0.301
Moderate/severe MR (n/%)	2 (6)	1 (6)	1.000
Systolic pulmonary AP (mmHg)	37 [33/49]	44 [33/68]	0.275
12-Item Short-Form Health Survey[§]			
Physical Component Summary	44.3 ± 10.6	47.5 ± 8.5	0.275
Mental Component Summary	47.2 ± 13.5	39.5 ± 11.3	0.043

Table 2 Demographic and clinical features according to basal ganglia motor dysfunction.

* Data are expressed as the mean value ± SD, median (interquartile range), or absolute numbers (percentage).

[§] Revised form of the 12-Item Short-Form Health Survey.

AP = artery pressure; MR = mitral regurgitation.

Neurological and psychiatric manifestations according to BGMD are shown in Table 3. The prevalence of OCS was much higher in patients with BGMD than those without (72% and 34%, respectively). Accordingly, higher scores on the Y-BOCS were associated with BGMD ($p = 0.004$). Major depressive disorder occurred in 56% of patients with BGMD whereas in only 22% of those without BGMD. Generalized anxiety disorder was also associated with BGMD ($p = 0.018$). There were no differences on the prevalence of prescribed antidepressants, anticonvulsants and benzodiazepines among patients with or without BGMD. No patient was using neuroleptics.

Migraine, cognitive complaints and seizures were frequent in the whole sample, not differing between groups. The score of the MCS of the SF-12v2 was significantly lower in patients with BGMD ($p = 0.043$), suggesting that neurological and behavioral symptoms influence the quality of life of these patients.

NEUROLOGICAL AND PSYCHIATRIC CHARACTERISTICS*	PATIENTS WITHOUT BASAL GANGLIA MOTOR DYSFUNCTION (N = 32)	PATIENTS WITH BASAL GANGLIA MOTOR DYSFUNCTION (N = 18)	P VALUE
Obsessive-compulsive symptoms	11 (34)	13 (72)	0.018
Major depressive disorder	7 (22)	10 (56)	0.028
Generalized anxiety disorder	13 (41)	14 (78)	0.018
Seizures	4 (13)	5 (28)	0.253
Migraine	14 (44)	12 (67)	0.149
Cognitive complaints	22 (69)	11 (61)	0.757
Prescribed Drugs			
Antidepressants	3 (9)	2 (11)	1.000
Anticonvulsants	2 (6)	3 (19)	0.336
Benzodiazepines	0 (0)	2 (11)	0.125
Validated Questionnaires			
YBOCS score [†]	0 [0/10.8]	13 [0/24]	0.004
HADS [‡] Depression	6.4 ± 4.8	8.7 ± 5.1	0.115
Anxiety	7.6 ± 5.0	9.9 ± 4.6	0.102
MMSE Score [§]	28 [25.5/30]	26 [24.8/29]	0.216
Low MMSE Score [¶]	8 (25)	8 (44)	0.211
FAB score [§]	14.5 [12/16.8]	14 [13/15.3]	0.895

Table 3 Neurological and psychiatric disorders according to basal ganglia motor dysfunction.

* Data are expressed as the mean value ± SD, median (interquartile range), or absolute numbers (percentage).

[†]Yale-Brown obsessive-compulsive scale.

[‡]Hospital Anxiety and Depression Scale.

[§]Mini-mental state examination.

[¶]MMSE scores below the cut-off proposed for Brazilian subjects, adjusted for schooling years.

[§]Frontal assessment battery.

In a multivariate logistic regression analysis, age (adjusted odds ratio [OR]: 0.916, 95% confidence interval [CI]: 0.853 to 0.985; $p = 0.018$), major depressive disorder (adjusted OR: 7.534, 95% CI: 1.528 to 37.148; $p = 0.013$) and Y-BOCS (adjusted OR: 1.101, 95% CI: 1.022 to 1.187; $p = 0.011$) emerged as variables independently associated with BGMD (Table 4). Generalized anxiety disorder and migraine did not remain in the final model.

VARIABLES	BASAL GANGLIA MOTOR DYSFUNCTION	
	OR (95% CI)	P VALUE
Age	0.916 (0.853 – 0.985)	0.018
Major depressive disorder	7.534 (1.528 – 37.148)	0.013
Y-BOCS [†]	1.101 (1.022 – 1.187)	0.011

Table 4 Factors independently associated with basal ganglia motor dysfunction.

[†]Yale-Brown obsessive-compulsive scale.

4. DISCUSSION

The current study determined the prevalence of neurological and psychiatric disorders in patients with RHD, evidencing a high prevalence of persistent chorea and tics. While the severity of heart disease was not associated with quality of life and clinically-defined BGMD, the latter was associated with younger age, major depressive disorder, and higher Y-BOCS scores.

There is a significant concern about long-term complications of RHD since it represents an important cause of cardiovascular morbidity and mortality in young patients, especially in low-income countries [3]. However, there is limited information on persistent chorea and other neurological and behavioral manifestations in adult patients with RHD. The available studies focused on neurological and psychiatric disorders in acute RF or persistent symptoms in adolescents and young adults with SC [8, 12–14, 31]. This is the first study to investigate the prevalence of chorea and other neurological and behavioral disorders in middle-aged adults with RHD.

SC is present in 20 to 30% of patients with acute RF and is frequently reported as a benign and self-limited condition. However, around 50% of patients with SC have chorea lasting more

than two years [32]. In the current study, all patients with RHD and chorea ($n = 11$, 22%) are presumably persistent SC since alternative causes of chorea were ruled out. The frequency of chorea of 22% in RHD is unexpectedly high since acute RF may have occurred as far as 20 to 30 years before. Interestingly, patients with BGMD were younger than those without BGMD, suggesting that the prevalence of chorea and tics may decrease over time. Future longitudinal studies must confirm this finding.

In acute RF, carditis may be present in up to 70% of patients with SC [5]. Although a well-recognized comorbidity, there are conflicting data on the potential association between SC and severity of carditis and development of RHD. While carditis was a marker of persistent chorea in a Brazilian study [32], Walker et al. (2007) reported that patients with carditis were less likely to display chorea, with a negative association between its severity and chorea [33]. A Turkish study could not establish any association between CS and RHD after following 12 SC patients with pure chorea for more than five years and not observing the development of RHD [34]. Our results did not show association between clinical and/or echocardiographic severity markers of RHD and BGMD, suggesting that motor signs, in other words chorea and tics, are not related to cardiac involvement. Since the severity of cardiac involvement is not necessarily associated with neurological signs indicating frontostriatal motor circuit impairment, the underlying pathophysiological processes of heart and brain dysfunction might be independent.

Behavioral disorders have been consistently associated with SC, notably OCS, depression, anxiety disorders [6]. There is also evidence that RF is associated with these disorders [5]. The landmark study of Swedo et al. (1989) described higher prevalence of OCS, anxiety and depressive symptoms among 23 SC patients compared to 14 RF patients without chorea [35]. Maia et al. (2005) confirmed a higher frequency of OCS in SC patients compared to those with RF and healthy controls [9]. In a more recent study, Moreira et al. (2014) reported that among 50 patients with SC consecutively evaluated, the most frequent psychiatric disorders were major depression (14%), generalized anxiety disorder (16%), social phobia (24%) and obsessive-compulsive disorder (OCD) (24%) [36]. They also reported a high prevalence of major depression in patients with persistent SC. Asbahr et al. (2004) found no difference in OCS prevalence between adult patients with RF and control patients with diabetes mellitus type 1 [12]. Conversely, Mercadante et al. (2000) reported that OCS were frequent in both RF patients with (22 patients) and without (20 patients) chorea [15]. In line with these findings, OCS have been reported to be more prevalent in 51 adult patients with RF and RHD (52.9%) compared to 46 control patients with non-rheumatic heart diseases (28.3%) [13]. We confirmed the high frequency of behavioral disorders in patients with RHD. The prevalence of OCS and major depressive disorder in our study were comparable to those reported in the literature for SC and RHD [9, 13, 36]. Generalized anxiety disorder was also highly prevalent, corroborating previous reports [15, 36].

Cognitive functions may be impaired in SC patients, as observed in other primary basal ganglia disorders such as Huntington's disease [8]. Individuals with SC may exhibit difficulties in executive functioning tasks and low performance in verbal fluency tests [6]. Adult patients who had chorea in childhood had worse performance in attention, speed information processing, executive functions and working memory tests compared to those who had RF without chorea [31]. Beato et al. (2010) reported that adult patients with both remitted and persistent SC had executive dysfunction, with no significant difference between both groups [8]. Decreased phonemic and semantic verbal fluency and impairment of verbal comprehension also occur in SC [10, 11]. We also performed brief cognitive assessment with MMSE and FAB to investigate whether global cognition and executive function impairment were associated with BGMD. Patients with BGMD and those without BGMD had similar performance in FAB and MMSE. A similar performance in these instruments was also noticed in patients with and without subjective cognitive complaints.

Increased prevalence of migraine in school children with SC and RF was previously reported [7]. The frequency of migraine in children and adolescents with SC (21.8%) and RF (18.2%) was higher than the estimated prevalence for this age group (3.2 to 10.6%) [7]. Our study is the first to describe the prevalence of migraine in middle-aged adults with RHD/RF. The prevalence of migraine in our sample (52%) is much higher than the estimated prevalence of migraine in the general Brazilian population (around 15%) [37].

There are anecdotal reports of the association of seizures with SC. Ch'ien et al. (1978) described two patients with SC who presented focal impaired awareness seizures among 28 SC patients [38]. Moreover, 60% of the sample had unspecific electroencephalographic abnormalities. As another original contribution, we found a high prevalence of seizure history in RHD (18%). Since we excluded RHD patients with stroke, seizures cannot be seen as a complication of cerebral ischemia. As a word of caution, it is not possible to rule out that, in some patients, seizures could be triggered by unknown causes other than SC.

It is worth highlighting that low scores in MCS of the SF-12v2 were associated with BGMD, which suggests a potential negative impact of mental health on social and occupational functioning of patients with clinical signs of impairment of frontostriatal motor circuit.

4.1. STUDY LIMITATIONS

The present study has several limitations. First, this study has a relatively small sample size, which might have underestimated the association of some variables, such as migraine, with BGMD. Conversely, we performed a comprehensive assessment of the patients, ruling out stroke and other conditions that might have inflated the results. Second, patients with RHD might represent a group of more severe RF, overestimating the prevalence of behavioral and neurological disorders. Nevertheless, RHD markers of severity did not associate with BGMD. Third, the high prevalence of female patients might have overestimated the prevalence of behavioral symptoms, but RHD is far more prevalent in women [1]. Fourth, seizures were very frequent in our population and we could not exclude other potential causes for epilepsy in all patients with seizures. Lastly, since this is a cross-sectional study, no cause-and-effect relationship can be inferred. A follow-up study is definitely warranted to elucidate the pattern of association/clustering and progression of these neurological and behavioral disorders over time and which factors are associated with their improvement and/or persistence.

5. CONCLUSION

Our study confirmed that neurological and behavioral disorders are remarkably frequent in middle-aged patients with RHD and may persist up to 20 to 30 years after RF, suggesting a persistent dysfunction of frontostriatal circuits. These disorders can also affect quality of life. The severity of heart disease was not related to the presence of clinical signs of BGMD, while younger age, major depressive disorder and OCS were. Similar to cardiac symptoms of RHD, such manifestations deserve a close attention from clinicians and researchers dealing with RF. Future studies are necessary for a better understanding of the factors and mechanisms underlying long-term behavioral and neurological symptoms persistence.

FUNDING INFORMATION

This study was partly funded by grants from CAPES, FAPEMIG and CNPq (Brazil). MCPN and ALT are CNPq scholarship recipients. ALT is funded by the UTHealth Houston Department of Psychiatry.

COMPETING INTERESTS

The authors have no competing interests to declare.

AUTHOR CONTRIBUTIONS

Conception and design of the research: LPBV, MCPN, and ALT; acquisition of data: LPBV, MCSB, FBMD, FAPO, PDL, BCMS, and LCBS; analysis and interpretation of data: JLPS, MCPN, ALT, and WAME; statistical analysis: JLPS and MCPN; writing of the manuscript: LPBV, MCPN and ALT; critical revision of the manuscript for intellectual content: all authors.

Luiz Paulo Bastos Vasconcelos

Post Graduate Program in Infectious Diseases and Tropical Medicine, School of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil

Marcelle Cristina da Silva Bastos Vasconcelos

Post Graduate Program in Infectious Diseases and Tropical Medicine, School of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil

Francisco Biagio Murta E. Di Flora

Post Graduate Program in Infectious Diseases and Tropical Medicine, School of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil

Flávio Augusto Paes de Oliveira

Post Graduate Program in Infectious Diseases and Tropical Medicine, School of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil

Pedro Drummond Lima

Post Graduate Program in Infectious Diseases and Tropical Medicine, School of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil

Lucas Campos Barbosa E. Silva

Post Graduate Program in Infectious Diseases and Tropical Medicine, School of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil

Breno Camargos Mucelli Spolaor

Post Graduate Program in Infectious Diseases and Tropical Medicine, School of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil

José Luiz Padilha da Silva

Department of Statistics, Universidade Federal do Paraná, Curitiba, PR, Brazil

William Antônio de Magalhães Esteves

Post Graduate Program in Infectious Diseases and Tropical Medicine, School of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil

Maria Carmo P. Nunes  orcid.org/0000-0001-8801-1828

Post Graduate Program in Infectious Diseases and Tropical Medicine, School of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil

Antônio Lúcio Teixeira  orcid.org/0000-0002-9621-5422

Faculdade Santa Casa BH, Belo Horizonte, MG, Brazil; and the Neuropsychiatry Program, UT Health Science Center, Houston, Texas, US

REFERENCES

1. **Carapetis JR, Beaton A, Cunningham MW**, et al. Acute rheumatic fever and rheumatic heart disease. *Nat Rev Dis Primers*. 2016; 2: 15084. DOI: <https://doi.org/10.1038/nrdp.2015.84>
2. **Zuhlke L, Engel ME, Karthikeyan G**, et al. Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study). *European Heart Journal*. 2015; 36: 1115–22a.
3. **Watkins DA, Johnson CO, Colquhoun SM**, et al. Global, Regional, and National Burden of Rheumatic Heart Disease, 1990–2015. *N Engl J Med*. 2017; 377: 713–722. DOI: <https://doi.org/10.1056/NEJMoa1603693>
4. **Cunningham MW**. Rheumatic fever, autoimmunity, and molecular mimicry: the streptococcal connection. *Int Rev Immunol*. 2014; 33: 314–29. DOI: <https://doi.org/10.3109/08830185.2014.917411>
5. **Vasconcelos LPB, Vasconcelos MC, Nunes MDCP, Teixeira AL**. Sydenham's chorea: an update on pathophysiology, clinical features and management. *Expert Opinion on Orphan Drugs*. 2019; 7: 501–511. DOI: <https://doi.org/10.1080/21678707.2019.1684259>
6. **Punukollu M, Mushet N, Linney M, Hennessy C, Morton M**. Neuropsychiatric manifestations of Sydenham's chorea: a systematic review. *Dev Med Child Neurol*. 2016; 58: 16–28. DOI: <https://doi.org/10.1111/dmcn.12786>
7. **Teixeira AL, Jr., Meira FC, Maia DP, Cunningham MC, Cardoso F**. Migraine headache in patients with Sydenham's chorea. *Cephalalgia*. 2005; 25: 542–4. DOI: <https://doi.org/10.1111/j.1468-2982.2004.00901.x>
8. **Beato R, Maia DP, Teixeira AL, Jr., Cardoso F**. Executive functioning in adult patients with Sydenham's chorea. *Mov Disord*. 2010; 25: 853–7. DOI: <https://doi.org/10.1002/mds.23154>
9. **Maia DP, Teixeira AL, Jr., Quintao Cunningham MC, Cardoso F**. Obsessive compulsive behavior, hyperactivity, and attention deficit disorder in Sydenham chorea. *Neurology*. 2005; 64: 1799–801. DOI: <https://doi.org/10.1212/01.WNL.0000161840.62090.0E>
10. **Harsanyi E, Moreira J, Kummer A, Meira ZM, Cardoso F, Teixeira AL**. Language Impairment in Adolescents With Sydenham Chorea. *Pediatr Neurol*. 2015; 53: 412–6. DOI: <https://doi.org/10.1016/j.pediatrneurol.2015.06.022>

11. **Cunningham MC, Maia DP, Teixeira AL, Jr., Cardoso F.** Sydenham's chorea is associated with decreased verbal fluency. *Parkinsonism Relat Disord.* 2006; 12: 165–7. DOI: <https://doi.org/10.1016/j.parkreldis.2005.11.003>
12. **Asbahr FR, Ramos RT, Costa AN, Sassi RB.** Obsessive-compulsive symptoms in adults with history of rheumatic fever, Sydenham's chorea and type I diabetes mellitus: preliminary results. *Acta Psychiatr Scand.* 2005; 111: 159–61. DOI: <https://doi.org/10.1111/j.1600-0447.2004.00455.x>
13. **Alvarenga PG, Hounie AG, Mercadante MT,** et al. Obsessive-compulsive symptoms in heart disease patients with and without history of rheumatic fever. *The Journal of Neuropsychiatry and Clinical Neurosciences.* 2006; 18: 405–8. DOI: <https://doi.org/10.1176/jnp.2006.18.3.405>
14. **de Alvarenga PG, Flores AC, Torres AR,** et al. Higher prevalence of obsessive-compulsive spectrum disorders in rheumatic fever. *Gen Hosp Psychiatry.* 2009; 31: 178–80. DOI: <https://doi.org/10.1016/j.genhosppsy.2008.11.003>
15. **Mercadante MT, Busatto GF, Lombroso PJ,** et al. The psychiatric symptoms of rheumatic fever. *The American Journal of Psychiatry.* 2000; 157: 2036–8. DOI: <https://doi.org/10.1176/appi.ajp.157.12.2036>
16. **Merriman NA, Sexton E, McCabe G,** et al. Addressing cognitive impairment following stroke: systematic review and meta-analysis of non-randomised controlled studies of psychological interventions. *BMJ Open.* 2019; 9: e024429. DOI: <https://doi.org/10.1136/bmjopen-2018-024429>
17. **Remenyi B, Wilson N, Steer A,** et al. World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease—an evidence-based guideline. *Nature reviews Cardiology.* 2012; 9: 297–309. DOI: <https://doi.org/10.1038/nrcardio.2012.7>
18. **Lang RM, Badano LP, Mor-Avi V,** et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Journal of the American Society of Echocardiography: Official Publication of the American Society of Echocardiography.* 2015; 28: 1–39. e14. DOI: <https://doi.org/10.1016/j.echo.2014.10.003>
19. **Nishimura RA, Otto CM, Bonow RO,** et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Thorac Cardiovasc Surg.* 2014; 148: e1–e132.
20. **Brucki SM, Nitrini R, Caramelli P, Bertolucci PH, Okamoto IH.** Suggestions for utilization of the mini-mental state examination in Brazil. *Arq Neuropsiquiatr.* 2003; 61: 777–81. DOI: <https://doi.org/10.1590/S0004-282X2003000500014>
21. **Beato R, Amaral-Carvalho V, Guimaraes HC,** et al. Frontal assessment battery in a Brazilian sample of healthy controls: normative data. *Arq Neuropsiquiatr.* 2012; 70: 278–80. DOI: <https://doi.org/10.1590/S0004-282X2012005000009>
22. **Zigmond AS, Snaith RP.** The hospital anxiety and depression scale. *Acta Psychiatr Scand.* 1983; 67: 361–70. DOI: <https://doi.org/10.1111/j.1600-0447.1983.tb09716.x>
23. **Goodman WK, Price LH, Rasmussen SA,** et al. The Yale-Brown Obsessive Compulsive Scale. II. Validity. *Archives of General Psychiatry.* 1989; 46: 1012–6. DOI: <https://doi.org/10.1001/archpsyc.1989.01810110054008>
24. **Goodman WK, Price LH, Rasmussen SA,** et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. *Archives of General Psychiatry.* 1989; 46: 1006–1011. DOI: <https://doi.org/10.1001/archpsyc.1989.01810110048007>
25. **Damásio BF, Andrade TF, Koller SH.** Psychometric Properties of the Brazilian 12-Item Short-Form Health Survey Version 2 (SF-12v2). *Paidéia (Ribeirão Preto).* 2015; 25: 29–37. DOI: <https://doi.org/10.1590/1982-43272560201505>
26. **Association AP.** *Diagnostic and statistical manual of mental disorders.* 5th edition. Arlington, VA: American Psychiatric Association, Ed; 2013.
27. **Augustine F, Singer HS.** Merging the Pathophysiology and Pharmacotherapy of Tics. *Tremor Other Hyperkinet Mov (N Y).* 2018; 8: 595. DOI: <https://doi.org/10.5334/tohm.442>
28. **Fisher RS, Cross JH, D'Souza C,** et al. Instruction manual for the ILAE 2017 operational classification of seizure types. *Epilepsia.* 2017; 58: 531–542. DOI: <https://doi.org/10.1111/epi.13671>
29. **Headache Classification Committee of the International Headache Society (IHS).** The International Classification of Headache Disorders, 3rd edition. *Cephalalgia.* 2018; 38: 1–211. DOI: <https://doi.org/10.1177/0333102417738202>
30. **Jessen F, Amariglio RE, Buckley RF,** et al. The characterisation of subjective cognitive decline. *The Lancet Neurology.* 2020; 19: 271–278. DOI: [https://doi.org/10.1016/S1474-4422\(19\)30368-0](https://doi.org/10.1016/S1474-4422(19)30368-0)
31. **Cavalcanti A, Hilario MO, dos Santos FH, Bolognani SA, Bueno OF, Len CA.** Subtle cognitive deficits in adults with a previous history of Sydenham's chorea during childhood. *Arthritis Care Res (Hoboken).* 2010; 62: 1065–71. DOI: <https://doi.org/10.1002/acr.20191>
32. **Cardoso F, Vargas AP, Oliveira LD, Guerra AA, Amaral SV.** Persistent Sydenham's chorea. *Mov Disord.* 1999; 14: 805–7. DOI: [https://doi.org/10.1002/1531-8257\(199909\)14:5<805::AID-MDS1013>3.0.CO;2-P](https://doi.org/10.1002/1531-8257(199909)14:5<805::AID-MDS1013>3.0.CO;2-P)

33. **Walker AR, Tani LY, Thompson JA, Firth SD, Veasy LG, Bale JF, Jr.** Rheumatic chorea: relationship to systemic manifestations and response to corticosteroids. *J Pediatr.* 2007; 151: 679–83. DOI: <https://doi.org/10.1016/j.jpeds.2007.04.059>
34. **Kilic A, Unuvar E, Tatli B,** et al. Neurologic and cardiac findings in children with Sydenham chorea. *Pediatr Neurol.* 2007; 36: 159–64. DOI: <https://doi.org/10.1016/j.pediatrneurol.2006.12.001>
35. **Swedo SE, Rapoport JL, Cheslow DL,** et al. High prevalence of obsessive-compulsive symptoms in patients with Sydenham's chorea. *The American Journal of Psychiatry.* 1989; 146: 246–9. DOI: <https://doi.org/10.1176/ajp.146.2.246>
36. **Moreira J, Kummer A, Harsanyi E, Cardoso F, Teixeira AL.** Psychiatric disorders in persistent and remitted Sydenham's chorea. *Parkinsonism Relat Disord.* 2014; 20: 233–6. DOI: <https://doi.org/10.1016/j.parkreldis.2013.10.029>
37. **Peres MFP, Queiroz LP, Rocha-Filho PS, Sarmiento EM, Katsarava Z, Steiner TJ.** Migraine: a major debilitating chronic non-communicable disease in Brazil, evidence from two national surveys. *The Journal of Headache and Pain.* 2019; 20: 85. DOI: <https://doi.org/10.1186/s10194-019-1036-6>
38. **Ch'ien LT, Economides AN, Lemmi H.** Sydenham's chorea and seizures. Clinical and electroencephalographic studies. *Archives of Neurology.* 1978; 35: 382–5. DOI: <https://doi.org/10.1001/archneur.1978.00500300056010>

TO CITE THIS ARTICLE:

Vasconcelos LPB, da Silva Bastos Vasconcelos MC, Di Flora FBME, de Oliveira FAP, Lima PD, Silva LCBE, Mucelli Spolaor BC, da Silva JLP, de Magalhães Esteves WA, Nunes MCP, Teixeira AL. Neurological and Psychiatric Disorders in Patients with Rheumatic Heart Disease: Unveiling what is Beyond Cardiac Manifestations. *Global Heart.* 2022; 17(1): 62. DOI: <https://doi.org/10.5334/gh.1149>

Submitted: 27 April 2021

Accepted: 01 August 2022

Published: 29 August 2022

COPYRIGHT:

© 2022 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See <http://creativecommons.org/licenses/by/4.0/>.

Global Heart is a peer-reviewed open access journal published by Ubiquity Press.